Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

No data on real-life experiences of risankizumab efficacy and safety are reported, apart from two isolated case reports. We carried out a single-centre, prospective study to assess the efficacy and safety of risankizumab. Fourteen patients were included (mean age 44.5 ± 14.2 years). Mean PASI decrea...

Full description

Saved in:
Bibliographic Details
Published in:Archives of dermatological research 2022-08, Vol.314 (6), p.619-623
Main Authors: Megna, Matteo, Cinelli, Eleonora, Gallo, Lucia, Camela, Elisa, Ruggiero, Angelo, Fabbrocini, Gabriella
Format: Article
Language:English
Subjects:
Clinical outcomes
Concise Communications
Dermatology
Drug resistance
Immunotherapy
Medicine
Medicine & Public Health
Monoclonal antibodies
Patient safety
Psoriasis
Safety
Scalp
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:No data on real-life experiences of risankizumab efficacy and safety are reported, apart from two isolated case reports. We carried out a single-centre, prospective study to assess the efficacy and safety of risankizumab. Fourteen patients were included (mean age 44.5 ± 14.2 years). Mean PASI decreased from 12.3 ± 5.2 (baseline) to 4.4 ± 2.7 at week 4 ( p  
ISSN:1432-069X
0340-3696
1432-069X
DOI:10.1007/s00403-021-02200-7